Biocryst Pharmaceuticals reported $34.28M in Selling and Administration Expenses for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
DBV Technologies DBVT:US 4.06M 1.37M
Alnylam Pharmaceuticals ALNY:US $ 154.47M 31.91M
Biocryst Pharmaceuticals BCRX:US $ 34.28M 1.1M
Chemocentryx CCXI:US $ 26.01M 2.72M
Chugai Pharma 4519:JP 25.26B 9.58B
Daiichi Sankyo 4568:JP 104.74B 14.78B
Enanta Pharmaceuticals ENTA:US $ 10.48M 968K
Gilead Sciences GILD:US $ 1.08B 567M
Glaxosmithkline GSK:US 2.68B 227M
GlaxoSmithKline GSK:LN 2.68B 227M
Intra Cellular Therapies ITCI:US $ 75.46M 4.22M
IONIS PHARMACEUT IONS:US $ 34.13M 3.47M
Karyopharm Therapeutics KPTI:US $ 38.77M 4.21M
Mirati Therapeutics MRTX:US $ 53.95M 10.42M
Novavax NVAX:US $ 95.99M 11.78M
Ptc Therapeutics PTCT:US $ 73.27M 13.28M
Regeneron Pharmaceuticals REGN:US $ 450M 109.6M
Sarepta Therapeutics SRPT:US $ 71.84M 6.22M
Ultragenyx Pharmaceutical RARE:US $ 67.31M 7.88M
Vertex Pharmaceuticals VRTX:US $ 215.2M 39.96M
YTE INCY:US $ 209.58M 16.62M